Marksans Pharma (NSE:MARKSANS) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Marksans Pharma's Free Cash Flow for the three months ended in Dec. 2023 was ₹0 Mil. Marksans Pharma's Revenue for the three months ended in Dec. 2023 was ₹5,861 Mil. Therefore, Marksans Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Marksans Pharma's current FCF Yield % is 2.55%.

The historical rank and industry rank for Marksans Pharma's FCF Margin % or its related term are showing as below:

NSE:MARKSANS' s FCF Margin % Range Over the Past 10 Years
Min: -11.31 Med: 6.53 Max: 15.36
Current: 8.75

During the past 13 years, the highest FCF Margin % of Marksans Pharma was 15.36%. The lowest was -11.31%. And the median was 6.53%.

NSE:MARKSANS's FCF Margin % is ranked better than
74.59% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.42 vs NSE:MARKSANS: 8.75

Marksans Pharma FCF Margin % Historical Data

The historical data trend for Marksans Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma FCF Margin % Chart

Marksans Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

1.44

15.36

9.66

3.58

9.94

Marksans Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Marksans Pharma's FCF Margin %

For the Drug Manufacturers - General subindustry, Marksans Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marksans Pharma's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's FCF Margin % falls into.

Marksans Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Marksans Pharma's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	1837.81	/	18496.19
	=	9.94 %

Marksans Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	5861.27
	=	0.00 %

Marksans Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Marksans Pharma (NSE:MARKSANS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

524404:India

Address

Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053

Website

http://www.marksanspharma.com

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines